Immunoneurology: A Serum Protein Afferent Limb to the CNS

  • Gerald P. Kozlowski
  • Gajanan Nilaver
  • Berislav V. Zlokovič
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 274)


The burgeoning field of neuroimmunology currently emphasizes a brain-immune link represented by hormones, neurotransmitters, neuropeptides, cytokines (1) and other substances of the CNS which are shared in common with the immune system and can act either directly or indirectly on components of the immune system or their target tissues. This concept essentially depicts the CNS as having an efferent outflow of active principles to a variety of peripheral structures. Another concept of potential importance in the maintenance of a homeostatic brain-immune interaction is that of immunoneurology, whereby principles derived from peripheral sources feed back onto the CNS. In this sense, immune cells, their products and other related substances can be transported from their source via the blood stream to the CNS wherein they may access the internal milieu and can, therefore, be considered afferent to the CNS. This review describes studies on transport of immunogammaglobulins (IgG) and albumins into the CNS of rat, rabbit and guinea pig using several techniques: immunocytochemistry (ICC), colchicine administration, active immunization, induced experimental allergic encephalomyelitis (EAE), radioisotope labeling, enzyme-linked immunosorbent assay (ELISA), rocket Immunoelectrophoresis and an in situ vascular brain perfusion method. Results from these studies reveal that serum albumin and globulin can enter the brain via several routes including that of active neuronal uptake by nerve endings, and subsequent transport to their cell bodies of origin via retrograde transport. These compounds may also enter the brain at circumventricular regions wherein functional leaks occur. Finally, there appears to be a saturable transport mechanism for IgG that is used to traverse the blood-brain barrier (BBB) and gain direct entry into the CNS.


Multiple Sclerosis Purkinje Cell Myelin Basic Protein Measle Virus Experimental Allergic Encephalitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dinarello, C.A., and J.W. Mier, Current concepts -lymphokines,N Engl J Med317: 940–945, 1987.PubMedGoogle Scholar
  2. 2.
    Nandy, K., Immune reactions in aging brain and senile dementia, In K. Nandy and I. Sherwin (eds)The Aging Brain and Senile Dementia, Advances in Behavioral Biology, Volume 23, Plenum Press, New York, pp. 181–196, 1977.Google Scholar
  3. 3.
    Nandy, K., Brain-reactive antibodies in aging and senile dementia, In R. Katzman, R. Terry, K. Bick (eds)Alzheimer’s Disease-Senile Dementia and Related Disorder, Raven Press, New York, pp. 503–512, 1978.Google Scholar
  4. 4.
    Neuwelt, E.A., and W.K. Clark, Unique aspects of the immunology of the central nervous system, InClinical Aspects of Neuroimmunology, Waverly Press, Baltimore, pp. 39–72, 1978.Google Scholar
  5. 5.
    Leibowitz, S., and R.A.C. Hughes, Immunology and the blood-brain barrier, InImmunology of the Nervous System, Edward Arnold, Ltd., London, pp. 1–19, 1983.Google Scholar
  6. 6.
    Bradbury, M.W., Transport across the blood-brain barrier, In E.A. Neuwelt (ed)Implication of the Blood-Brain Barrier and Its Manipulation, Volume I, Plenum Medical Book Company, New York, pp. 119–136, 1989.Google Scholar
  7. 7.
    Broadwell, R.D., and M. Salcman, Expanding the definition of the blood-brain barrier to protein,Proc Natl Acad Sci USA78: 7820–7824, 1981.PubMedGoogle Scholar
  8. 8.
    Broadwell, R.D., B.J. Balin, and M. Salcman, Transcytotic pathway for blood-borne protein through the blood-brain barrier,Proc Natl Acad Sci USA85: 632–636, 1988.PubMedGoogle Scholar
  9. 9.
    Broadwell, R.D., B.J. Balin, M. Salcman, and R.S. Kaplan, Brain-blood barrier? Yes and no,Proc Natl Acad Sci USA80: 7352–7356, 1983.PubMedGoogle Scholar
  10. 10.
    Oldendorf, W.H., Permeability of the blood-brain barrier, In D.B. Tower, R.O. Brady, D.P. Purpura, C.D. Clemente, W.M. Landau, and S.E. Mayer SE (eds)The Nervous System, Volume 1, Raven Press, New York, pp. 279–89, 1975.Google Scholar
  11. 11.
    Blatteis, C.M., N. Quan, and R.D. Howell, The Organum vasculosum laminae terminalis (OVLT) is critical for fever induced in guinea pigs by blood-borne cytokines,Soc Neurosci Abstr15: 718, 1989.Google Scholar
  12. 12.
    Brightman, M.W., and T.S. Reese, Junctions between intimately apposed cell membranes in the vertebrate brain, JCell Biol40: 648–677, 1969.PubMedGoogle Scholar
  13. 13.
    Blatteis, C.M., W.S. Hunter, J.M. Wright, RA. Ahokas, Q.J. Llanos, and T.A. Mashburn, Jr., Thermoregulatory responses of guinea pigs with anteroventral third ventricle lesions,Can J Physiol Pharmacol65: 1261–1266, 1987.PubMedGoogle Scholar
  14. 14.
    Balin, B.J., R.D. Broadwell, M. Salcman, and M. El-Kalliny, Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey, JComp Neurol251: 260–280, 1986.PubMedGoogle Scholar
  15. 15.
    Broadwell, R.D., and M.W. Brightman, Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood, JComp Neurol166: 257–283, 1976.PubMedGoogle Scholar
  16. 16.
    Broadwell, R.D., and M.W. Brightman, Cytochemistry of undamaged neurons transporting exogenous proteinin vivo, J Comp Neurol185: 31–73, 1979.PubMedGoogle Scholar
  17. 17.
    Nilaver, G., H. Brem, and E.A. Zimmerman, Immunocytochemical localization of albumin in rat brain,Neurology32: A107, 1982.Google Scholar
  18. 18.
    Sparrow, J.R., Immunocytochemical localization of plasma protein in neuronal perikarya,Brain Res212: 159–163, 1981.PubMedGoogle Scholar
  19. 19.
    Kozlowski, G.P., and W.L. Dees, Immunocytochemistry for LHRH neurons in the arcuate nucleus of the rat: fact or artifact? JHistochem Cytochem32:83–91, 1984.PubMedGoogle Scholar
  20. 20.
    Meeker, M.L., R.B. Meeker, and J.N. Hayward, Accumulation of circulating endogenous and exogenous immunoglobulins by hypothalamic magnocellular neurons,Brain Res423: 45–55, 1987.PubMedGoogle Scholar
  21. 21.
    Fabian, R.H., and G. Petroff, Intraneuronal IgG in the central nervous system: update by retrograde axonal transport,Neurology37: 1780–1784, 1987.PubMedGoogle Scholar
  22. 22.
    Baker, H., and R.F. Spencer, Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat,Exp Brain Res63:461–473,1986.PubMedGoogle Scholar
  23. 23.
    Harrison, P.J., H. Hultborn, E. Jankowska, R. Katz, B. Storai, and D. Zytnicki, Labelling of interneurones by retrograde transsynaptic transport of horseradish peroxidase from motoneurones in rats and cats,Neurosci Lett45: 15–19, 1984.PubMedGoogle Scholar
  24. 24.
    Ugolini, G., H.G.J.M. Kuypers, and A. Simmons, Retrograde transneuronal transfer of Herpes simplex virus type 1 (HSV 1) from motorneurons,Brain Res422: 242–256, 1987.PubMedGoogle Scholar
  25. 25.
    Jones, E.G., and B.K. Hartman, Recent advances in neuroanatomical methodology,Ann Rev Neurosci1: 215–296, 1978.PubMedGoogle Scholar
  26. 26.
    Reiber, H., A.J. Suckling, and M.G. Rumsby, The effect of Freund’s adjuvants on blood-cerebrospinal fluid barrier permeability, JNeurol Sci63: 55–61, 1984.PubMedGoogle Scholar
  27. 27.
    Kozlowski, G.P., and G. Nilaver, Immunoelectron microscopy of neuropeptides: theoretical and technical considerations, In J.L. Barker and J.F. McKelvy (eds)Current Methods in Cellular Neurobiology, John Wiley and Sons, Inc., New York, pp. 133–174, 1983.Google Scholar
  28. 28.
    Peress, N.S., J. Siegelman, and H.B. Fleit, High avidity periventricular IgG-Fc receptor activity in human and rabbit brain,Clin Immunol Immunopath 42: 229–238, 1987.Google Scholar
  29. 29.
    Segal, M.B., and B.V. Zlokovič,The Blood-Brain Barrier, Amino Acids and Peptides, Kluwer Academic Publishers, London, pp. 1–11, 1989.Google Scholar
  30. 30.
    Reese, T.S., and M.J. Karnovsky, Fine structural localization of a blood-brain barrier to exogenous peroxidase, JCell Biol34: 207–217, 1967.PubMedGoogle Scholar
  31. 31.
    Broadwell, R., A. Wolf, and M. Tangoren, Transcytosis of blood-borne ferrotransferrin and insulin through the blood-brain barrier,Soc Neurosci Abstr15: 821, 1989.Google Scholar
  32. 32.
    Pardridge, W.M., Receptor-mediated peptide transport through the blood-brain barrier,Endocr Review7: 314–330, 1986.Google Scholar
  33. 33.
    Pardridge, W.M., Recent advances in blood-brain barrier transport,Ann Rev Pharmacol Toxicol28: 25–39, 1988.Google Scholar
  34. 34.
    Zlokovič, B.V., V.T. Susic, H. Davson, DJ. Begley, R.M. Jankov, D.M. Mitrovič, and M.N. Lipovac, Saturable mechanism for delta-sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea-pig brain,Peptides10: 249–254, 1989.PubMedGoogle Scholar
  35. 35.
    Zlokovič, B.V.,In vivoapproaches for studying peptide interactions at the blood-brain barrier, JControl Rel, In Press.Google Scholar
  36. 36.
    Zlokovič, B.V., J.B. Mackič, B. Djuricič, and H. Davson, Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain barrier of anin situperfused guinea-pig brain, JNeurochem, 53: 1333–1340, 1989.PubMedGoogle Scholar
  37. 37.
    Kozlowski, G.P., and G. Nilaver, Structural and functional relationships between the immune and central nervous systems in Alzheimer’s Disease,Drug Dev Res15: 129–142, 1988.Google Scholar
  38. 38.
    Zlokovič, B.V., D.J. Begley, B.M. Djuricič, and D.M. Mitrovič, Measurement of solute transport across the blood-brain barrier in the perfused guinea-pig brain: method and application of N-methyl-alphaaminoisobutric acid, JNeurochem46: 1444–1451, 1986.PubMedGoogle Scholar
  39. 39.
    Zlokovič, B.V., D.S. Skundric, M.B. Segal, M.N. Lipovac, J.B. Mackič, and H. Davson, A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea-pig,Exp Neurol, In Press.Google Scholar
  40. 40.
    Zlokovič, B.V., D.S. Skundric, M.B. Segal, J. Colover, R.M. Jankov, N. Pejnovič, V. Lackovič, J.B. Mackič, M.N. Lipovac, H. Davson, E. Kasp, D. Dummonde, and L.J. Lackovič, Blood-brain barrier permeability changes during acute allergic encephalomyelitis induced in the guinea-pig,Metab Brain Dis4: 33–40, 1989.PubMedGoogle Scholar
  41. 41.
    Erlendsson, K., T. Swartz, and J.M. Dwyer, Successful reversal of echo virus encephalitis in x-linked hypogammaglobulinemia by intraventricular administration of immunoglobulin,N Engl J Med312: 351–353, 1985.PubMedGoogle Scholar
  42. 42.
    Keenan, A.M., J.C. Harbert, and S.M. Larson, Monoclonal antibodies in nuclear medicine, JNucl Med26: 531–537, 1985.PubMedGoogle Scholar
  43. 43.
    Colover, J., Acute demyelination in EAE after pretreatment with foreign protein and muramyl dipeptide (MDP),In A.R.Liss (ed)ExperimentalAllergic Encephalomyelitis: A Useful Model for Multiple Sclerosis, Alan R. Liss, New York, pp. 37–41, 1984.Google Scholar
  44. 44.
    Pardridge, W.M., J. Eisenberg, and J. Yang, Human blood-brain barrier insulin receptor, JNeurochem44: 1771–1778, 1985.PubMedGoogle Scholar
  45. 45.
    Frank, H.J.L., W.M. Pardridge, W.L. Morris, R.G. Rosenfeld, and T.B. Choi, Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels,Diabetes35: 654–661, 1986.PubMedGoogle Scholar
  46. 46.
    Kumagai, A.K., J.B. Eisenberg, and W.M. Pardridge, Absorptive-mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptides by isolated brain capillaries. Model system of blood-brain transport, JBiol Chem262: 15214–15219, 1987.PubMedGoogle Scholar
  47. 47.
    Pardridge, W.M., J. Eisenberg, and J. Yang, Human blood-brain barrier transferrin receptor,Metabolism Clin Exper36: 892–895, 1987.Google Scholar
  48. 48.
    Triguero, D., J.B. Buciak, J. Yang, and W.M. Pardridge, Blood-brain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein,Proc Natl Acad Sci USA86, 4761–4765, 1989.PubMedGoogle Scholar
  49. 49.
    Zlokovič, B.V., D.J. Begley, M.B. Segal, H. Davson, L.J. Rakič, M.N. Lipovac, D.M. Mitrovič, and R.M. Jankov, Neuropeptide transport mechanisms in the central nervous system, In L.J. Rakič, D.J. Begley, H. Davson, and B.V. Zlokovič (eds)Peptide and Amino Acid Transport Mechanisms in the Central Nervous System, Macmillan Press Ltd, London, pp. 3–21, 1988.Google Scholar
  50. 50.
    Zlokovič, B.V., M.N. Lipovac, D.J. Begley, H. Davson, and L. Rakič, Transport of leucin-enkephalin across the blood-brain barrier in the perfused guinea-pig brain, JNeurochem49: 310–315, 1987.PubMedGoogle Scholar
  51. 51.
    Zlokovič, B.V., M.B. Segal, H. Davson, and D.M. Mihovič, Unidirectional uptake of enkephalins at the blood-tissue interface of the blood-cerebrospinal fluid barrier: a saturable mechanism,Regul Peptides20: 33–44, 1988.Google Scholar
  52. 52.
    Zlokovič, B.V., M.B. Segal, H. Davson, and R.M. Jankov, Passage of delta-sleep-inducing peptide (DSIP) across the blood-cerebrospinal fluid barrier,Peptides9: 533–538, 1988.PubMedGoogle Scholar
  53. 53.
    Colover, J., A new pattern of spinal-cord demyelination in guinea pigs with acute experimental allergic encephalomyelitis mimicking multiple sclerosis,Br I Exp Biol Pathol61: 390–400, 1980.Google Scholar
  54. 54.
    Colover, J., and A. Qureshi Myelin debris in demyelinating process: a disease activity marker? In C. Confavreux, G. Aimard, and M. Devič (eds)Trends in European Multiple Sclerosis Research, Elsevier, London, pp. 229–234, 1988.Google Scholar
  55. 55.
    Wekerle, H., C. Linnington, H. Lassmann, and R. Meyerman, Cellular immune reactivity within the CNS,Trends in Neurosci9: 271–277, 1986.Google Scholar
  56. 56.
    Fontana, A., Astrocytes and lymphocytes: intercellular communication by growth factors, JNeurosci Res8: 443–451, 1982.PubMedGoogle Scholar
  57. 57.
    Lampson, L.A., and W.F. Hickey, Monoclonal antibody analysis of MHC expression in human brain biopsies: tissues ranging from “histologically normal” to that showing different levels of glial tumor involvement,J Immunol136: 4054–4062, 1986.PubMedGoogle Scholar
  58. 58.
    Luber-Narod, J., and J. Rogers, Immune system associated antigens expressed by cells of the human central nervous system,Neurosci Lett94: 17–22, 1988.PubMedGoogle Scholar
  59. 59.
    McCarron, R.M., O. Kempski, M. Spatz, and D.E. McFarlin, Presentation of myelin basic protein by murine cerebral vascular endothelial cells, JImmunol134: 3100–3103, 1985.PubMedGoogle Scholar
  60. 60.
    Leibowitz, S., and R.A.C. Hughes, The immune response in the central nervous system, InImmunology of the Nervous System, Edward Arnold, Ltd., London, pp. 20–40, 1983.Google Scholar
  61. 61.
    Wong, G.H.W., P.F. Bartlett, I. Clark-Lewis, J.L. McKimm-Breschkin, and J.W. Schrader, Interferon-λ induces the expression of H-2 and Ia antigens on brain cells, JNeuroimmunol7: 255–278, 1985.PubMedGoogle Scholar
  62. 62.
    Massa, P.T., R. Dorries, ter Muelen, Viral particles induce Ia antigen expression on astrocytes,Nature320: 543–546, 1986.PubMedGoogle Scholar
  63. 63.
    Sotelo, J., C.J. Gibbs, Jr., and D.C. Gajdusek, Autoantibodies against axonal neurofilaments in patients with kuru and Creuetzfeld-Jacob disease,Science210: 190–193, 1980.PubMedGoogle Scholar
  64. 64.
    Antoniou, A.V., H. El-Sady, C. Butler, and J.L. Turk, The modulation of class II histocompatibility antigens and activated macrophage determinants in the spinal cord during the development of chronic relapsing experimental allergic encephalomyelitis (CREAE) in the guinea pig -relevance to the induction of remission, JNeuroimmunol15: 57–71, 1987.PubMedGoogle Scholar
  65. 65.
    Matsumoto, Y., N. Hara, R. Tanaka, M. Fugiwara, Immunohistochemical analysis of rat central nervous system during experimental allergic encephalomyelitis, with special reference to Ia-positive cells with dendritic morphology, JImmunol136: 3668–3676, 1986.PubMedGoogle Scholar
  66. 66.
    Neuwelt, E.A., and W.K. Clark, The immunology of demyelinating disease, InClinical Aspects of Neuroimmunology, Waverly Press, Baltimore, pp. 233–72, 1978.Google Scholar
  67. 67.
    Chou, C.H.J., F.C.H. Chou, W.W. Tourtellotte, and R.F. Kibler, Search for a multiple sclerosis specific brain antigen,Neurology33: 1300–1304, 1983.PubMedGoogle Scholar
  68. 68.
    Gannuszkina, I.W., H. Weinrauder, and I.G. Zirnowa, Use of the immunofluorescence and immunodiffusion methods for the detection of anti-brain antibodies in sera of patients with central nervous system diseases,Neurpath Pol21: 183–190, 1983.Google Scholar
  69. 69.
    Johnson, A.B., and M.B. Bornstein, Myelin binding antibodiesin vitro: immunoperoxidase studies with experimental allergic encephalomyelitis, anti-galactocerebroside and multiple sclerosis sera,Brain Res159: 173–182, 1978.PubMedGoogle Scholar
  70. 70.
    Lisak, R.P., R.G. Heinze,G.A. Falk, and M.W. Keis, Search for antiencephalitogen antibodies in human demyelinating diseases,Neurology18: 122–128, 1968.PubMedGoogle Scholar
  71. 71.
    Paterson, P.Y., Autoimmune neurologic disease: experimental animal systems and implications for multiple sclerosis, In N. Talal (ed)Autoimmunity. Genetic Immunologic Virologic and Clinical Aspects, Academic Press, New York, pp. 643–707, 1977.Google Scholar
  72. 72.
    Rostrom, B., Specificity of antibodies in oligoclonal bands in patients with multiple sclerosis and cerebrovascular disease,Acta Neurol Scand63 [Suppl 86]: 10–84, 1981.Google Scholar
  73. 73.
    Wisniewski, H.M., Immunopathology of demyelination and autoimmune disease and virus infections,Brit Med Bull33: 54–59, 1977.PubMedGoogle Scholar
  74. 74.
    Arnason, B.G.W., Clinical immunology, In D.B.Tower, T.N. Chase, A.L. Sahs, P.R. Dodge, H.L. Heyl, R.J. Joynt, E.S. Goldenshon, R. DeJong, and A. Pope (eds)The Nervous System, Volume 2, Raven Press, New York, pp. 61–66, 1975.Google Scholar
  75. 75.
    Dean, G., The multiple sclerosis problem,Sci Amer223: 40–46, 1970.PubMedGoogle Scholar
  76. 76.
    Lisak, R.P., B. Zweiman, J.B. Burns, A. Rostami, and D.H. Silberberg, Immune responses to myelin antigens in multiple sclerosis,Ann NY Acad Sci436: 221–232, 1984.PubMedGoogle Scholar
  77. 77.
    Lisak, R.P., and B. Zweiman,In vitrocell-mediated immunity of cerebrospinal fluid lymphocytes to myelin basic protein in primary demyelinating diseases,New Eng J Med297: 850–853, 1977.PubMedGoogle Scholar
  78. 78.
    Lisak, R.P., B. Zweiman, D. Waters, H. Koprowski, and D.E. Pleasure, Cell-mediated immunity to measles, myelin basic protein and central nervous system extract in multiple sclerosis: a longitudinal study employing direct buffy coat migration assays,Neurology28: 798–803, 1978.PubMedGoogle Scholar
  79. 79.
    Lisak, R.P., B. Zweiman, and J.N. Whitaker, Spinal fluid basic protein immunoreactive material and spinal fluid lymphocyte reactivity to basic protein,Neurology31: 180–182, 1981.PubMedGoogle Scholar
  80. 80.
    Fujinami, R.S., and M.B.A. Oldstone, Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanisms for autoimmunity,Science230: 1043–1045, 1985.PubMedGoogle Scholar
  81. 81.
    Fraser, K.B., Population serology, In A.N. Davison, J.H. Humphrey, A.L. Liversedge, W.I. McDonald, and J.S. Porterfield, (eds)Multiple Sclerosis Research, Elsevier, New York, pp. 53–79, 1975.Google Scholar
  82. 82.
    Petz, L.D., G.C. Sharp, N.R. Cooper, and W.S. Irvin, Serum and cerebrospinal fluid complement and serum autoantibodies in systemic lupus erythematosus,Medicine(Baltimore) 50: 259–275, 1971.Google Scholar
  83. 83.
    Rostagi, S.C., J. Clausen, H. Offner, G. Konat, and T. Fog, Partial purification of MS brain-specific antigen,Acta Neurol Scand59: 281–296, 1979.Google Scholar
  84. 84.
    Mulles, K.B., and FA. Faloona, Specific synthesis of DNA in vitro via a polymerase catalyzed chain reaction,Meth Enzymol155: 335, 1987.Google Scholar
  85. 85.
    Saikai, R.K., D.H. Gelfand, S. Stoffel, S.J. Scharf, R. Higuchi, G.T. Horn, K.B. Mullis, and HA. Erlich, Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase,Science239: 487–491, 1988.Google Scholar
  86. 86.
    Duggan, D.B., G.D. Ehrhch, F.P. Davey, S. Kwok, J. Sninsky, J. Goldberg, L. Baltrucki, and B.J. Poiesz, HTLV-1 induced lymphoma mimicking Hodgkin’s disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-1 sequences in tumor DNA,Blood71: 1027–1032, 1988.PubMedGoogle Scholar
  87. 87.
    Manzari, V., A. Gismondi, G. Barellari, S. Morrone, A. Modesti, L. Albonici, L. de Marchis, V. Fazio, A. Gradilone, M. Zani, L. Frati, and A. Santoni, HTLV-V: a new human retrovirus isolated in a tacnegative T-cell lymphoma/leukemia,Science238: 1581–1583, 1987.PubMedGoogle Scholar
  88. 88.
    Resnick, L., J.R. Berger, P. Shapshak, and W.W. Tourtellotte, Early penetration of the blood-brain-barrier by HIV,Neurology38: 9–14, 1988.PubMedGoogle Scholar
  89. 89.
    Koprowski, H., E.C. de Freitas, M.E. Harper, M. Sandberg-Wollheim, WA. Sheremata, M. Robert-Guroff, C.W. Saxinger, M.B. Feinberg, F. Wong-Staal, and R.C. Gallo, Multiple sclerosis and human T-cell lymphotropic retroviruses,Nature318: 154–160, 1985.PubMedGoogle Scholar
  90. 90.
    Reddy, E.P., M. Sandberg-Woelheim, R.V. Meltus, P.E. Ray, E. deFreitas, and H. Koprowski, Amplification and molecular cloning of HTLV-I sequences from DNA of multiple sclerosis patients,Science243: 529–533, 1989.PubMedGoogle Scholar
  91. 91.
    Greenberg, S.J., G.D. Ehrlich, M.A. Abbott, BJ. Hurwitz, TA. Waldmann, and B.J. Poiesz, Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification,Proc Natl Acad Sci USA86: 2878–2882, 1989.PubMedGoogle Scholar
  92. 92.
    Fraser, K.B., Multiple Sclerosis, a viral disease?Brit Med Bull33: 34–39, 1977.PubMedGoogle Scholar
  93. 93.
    Johnson, R.T., Virological data supporting the viral hypothesis in multiple sclerosis, In A.N. Davison, J.H. Humphrey, A.L. Liversedge, W.I. McDonald, and J.S. Porterfield, (eds)Multiple Sclerosis Research, Elsevier, New York, pp. 155–183, 1975.Google Scholar
  94. 94.
    Höcker, P., V. Stellamor, K. Summer, and M. Mann, Plasma exchange (PE) and lymphocytapheresis (LCA) in multiple sclerosis (MS),Int J Artif Organs7: 39–42, 1984.PubMedGoogle Scholar
  95. 95.
    Khatri, B.O., S.M. Koethe, and M.P. McQuillen, Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis: a pilot study,Arch Neurol41: 734–738, 1984.PubMedGoogle Scholar
  96. 96.
    Khatri, B.O., M.P. McQuillen, G.J. Harrington, D. Schmoll, and R.G. Hoffman, Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs,Neurology35: 312–319, 1985.PubMedGoogle Scholar
  97. 97.
    Ghezzi, A., M. Zaffaroni, D. Caputo, R. Guaschino, P. Gasco, R. Montanini, and C.L. Cazzullo, Lymphocytoplasmapheresis in multiple sclerosis: preliminary laboratory findings,Ital J NeurolSci 6: 85–87, 1985.PubMedGoogle Scholar
  98. 98.
    Hauser, S.L., M. Fosberg, S.V. Kevy, and H.L. Weiner, Lymphocytopheresis in chronic progressive multiple sclerosis: immunologic and clinical effects,Neurology34: 922–926, 1984.PubMedGoogle Scholar
  99. 99.
    Tindall, R.S.A., J.E. Walker, A.L. Ehle, L. Near, J. Rollins, and D. Becker, Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone,Neurology32: 739–743, 1982.PubMedGoogle Scholar
  100. 100.
    Cook, S.D., C. Devereux, R. Troiano, M.P. Hafstein, G. Zito, E. Hernandy, M. Larvenhar, R. Vidaver, and P.C. Dowling, Effect of total lymphoid irradiation in chronic progressive multiple sclerosis,Lancet1: 1405–1409, 1986.PubMedGoogle Scholar
  101. 101.
    Gebhart, W., S. Schuller-Petrovic, H. Lassmann, and D. Kraft, NK cells and the nervous system,Wein Klin Wochenschr95: 828–831, 1983.Google Scholar
  102. 102.
    Brain, L., and M. Wilkinson, Subacute cerebellar degeneration associated with neoplasms,Brain88: 465–478, 1965.PubMedGoogle Scholar
  103. 103.
    Greenlee, J.E., and H.R. Brashear, Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma,Ann Neurol14: 609–613, 1983.PubMedGoogle Scholar
  104. 104.
    Jaeckle, K.A., F. Graus, A. Houghton, C. Cordon-Cardo, S.L. Nielsen, and J.B. Posner, Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic antigen,Ann Neurol18: 592–600, 1985.PubMedGoogle Scholar
  105. 105.
    Kearsley, J.H., P. Johnson, and M. Halmagyi, Paraneoplastic cerebellar disease: remission with excision of the primary tumor,Arch Neurol42: 1208–1210, 1985.PubMedGoogle Scholar
  106. 106.
    Cunningham, J., F. Graus, N. Anderson, and J.B. Posner, Partial characterization of Purkinje cell antigens in paraneoplastic cerebellar degeneration,Neurology36: 1163–1168, 1986.PubMedGoogle Scholar
  107. 107.
    Brain, W.R., P.M. Daniel, and J.G. Greenfield, Subacute cortical cerebellar degeneration and its relation to carcinoma, JNeurol Neurosurg Psych14: 59–75, 1951.Google Scholar
  108. 108.
    Henson, RA., and H. Urich, Remote effects of malignant disease: certain intracranial disorders, In P.J. Vinken, G.W. Bruyn, and H.L. Klawans (eds)Handbook of Clinical Neurology, Volume 38, North-Holland Publishing, Amsterdam, pp. 625–668, 1979.Google Scholar
  109. 109.
    Hammack, J.E., D.W. Kimmel, B.P. O’Neill, and VA. Lennon, Comparison of patients with paraneoplastic cerebellar degeneration (PCD) who are seropositive and seronegative for Purkinje cell cytoplasmic antibodies (PCAb),Neurology38 [Suppl 1]: 127, 1988.Google Scholar
  110. 110.
    Jaeckle, K.A., and J.E. Greenlee, Immunohistochemical patterns of antibody response in paraneoplastic neurological syndromes correlate with specific syndromes and with tumor types,Ann Neurol24: 121, 1988.Google Scholar
  111. 111.
    Smith, J.L., J.C. Finley, and VA. Lennon, Autoantibodies in paraneoplastic cerebellar degeneration bind to cytoplasmic antigens of Purkinje cells in humans, rats, and mice and are of multiple immunoglobulin classes, JNeuroimmunol18: 37–48, 1988.PubMedGoogle Scholar
  112. 112.
    Anderson, N., M.K. Rosenbaum, and J.B. Posner, Paraneoplastic cerebellar degeneration: clinical-immunological correlations,Ann Neurol24: 559–567, 1988.PubMedGoogle Scholar
  113. 113.
    Paone, J.F., and K. Jeyasingham, Remission of cerebellar dysfunction after pneumonectomy for bronchogenic carcinoma,New Eng J Med302: 156,1980.PubMedGoogle Scholar
  114. 114.
    Cocconi, G., G. Leci, G. Juvarra, M.R. Monopoli, T. Cocchi, F. Fraccadori, A. Lechi, and P. Boni, Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis: a case report,Cancer56: 2318–2320, 1985.PubMedGoogle Scholar
  115. 115.
    Dropcho, E.J., Y.T. Chen, J.B. Posner, and L.J. Old, Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration,Proc Natl Acad Sci USA84: 4552–4556, 1987.PubMedGoogle Scholar
  116. 116.
    Furneaux, H.M., E.J. Dropcho, D. Barbut, Y.T. Chen, M.K. Rosenblum, L.J. Old, and J.B. Posner, Characterization of a cDNA encoding a 34-kDa Purkinje neuron protein recognized by sera from patients with paraneoplastic cerebellar degeneration,Proc Natl Acad Sci USA86: 2873–2877, 1989.PubMedGoogle Scholar
  117. 117.
    Borges, L.F., P.J. Elliot, R. Gill, S.D. Iversen, and L.L. Iversen, Selective extraction of small and large molecules from the cerebrospinal fluid by Purkinje neurons,Science 228: 346–348, 1985.PubMedGoogle Scholar
  118. 118.
    Jaeckle, K.A., W.G. Stroop, J.E. Greenlee, M. Price, and Q.S. Deng, Intraventricular injection of paraneoplastic anti-Purkinje cell antibody in a rat model,Neurology36: 332, 1986.Google Scholar
  119. 119.
    Wisniewski, H.M., and R.D. Terry, Neuropathology of the aging brain, In R.D. Terry and S. Gershon (eds)Neurobiology of Aging, Raven Press, New York, pp. 265–280, 1976.Google Scholar
  120. 120.
    Ishii, T., S. Haga, and F. Shimizu, Identification of components of immunoglobulins in senile plaques by means of fluorescent technique,Acta Neuropath32: 157–162, 1975.PubMedGoogle Scholar
  121. 121.
    Eikelenboom, P., and F.C. Stam, Immunoglobulins and complement factors in senile plaques,Acta Neuropathol57: 239–242, 1982.PubMedGoogle Scholar
  122. 122.
    Ishii, T., and S. Haga, Immunoelectron microscopic localization of complements in amyloid fibrils of senile plaques,Acta Neuropathol63: 296–300, 1984.PubMedGoogle Scholar
  123. 123.
    Schechter, R., S.H.C. Yen, and R.D. Terry, Fibrous astrocytes in senile dementia of Alzheimer type, JNeuropath Exp Neurol40: 95–101, 1981.PubMedGoogle Scholar
  124. 124.
    Hildemann, W.H.,Essentials of Immunology, Elsevier, New York, pp. 114, 1984.Google Scholar
  125. 125.
    Elovaara, I., A. Icen, J. Palo, and T. Erkinjuntti, CSF in Alzheimer’s disease. Studies on blood-brain barrier function and intrathecal protein synthesis, JNeurol Sci70: 73–80, 1985.PubMedGoogle Scholar
  126. 126.
    Elovaara, I., J. Palo, T. Erkinjuntti, and R. Sulkava, Serum and cerebrospinal fluid proteins and the blood-brain barrier in Alzheimer’s disease and multi-infarct dementia,Eur Neurol26: 229–234, 1987.PubMedGoogle Scholar
  127. 127.
    Rogers, J., J. Luber-Narod, S.D. Styren, and W.H. Civin, Expression of immune system-associated antigens by cells of the human nervous system: relationship to pathology of Alzheimer’s disease,Neurobiol Aging9: 339–349, 1988.PubMedGoogle Scholar
  128. 128.
    Della-Fera, M.A., and C.S. Baile, Cholecystokinin octapeptide: continuous picomole injections into the cerebral ventricles of sheep suppress feeding,Science206: 471–473, 1979.PubMedGoogle Scholar
  129. 129.
    Lind, R.W., L.W. Swanson, and D. Ganten, Organization of angiotensin II immunoreactive cells and fibers in the rat central nervous system. An immunohistochemical study,Neuroendocrinology40: 2–24, 1985.PubMedGoogle Scholar
  130. 130.
    Saper, C.B., D.G. Standaert, M.G. Currie, D. Schwartz, D.M. Geller, and P. Needleman, Atriopeptin-immunoreactive neurons in the brain: presence in cardiovascular regulatory areas,Science227: 1047–1049, 1985.PubMedGoogle Scholar
  131. 131.
    Breder, C.D., CA. Dinarello, and C.B. Saper, Interleukin-1 immunoreactive innervation of the human hypothalamus,Science240: 321–234, 1988.PubMedGoogle Scholar
  132. 132.
    Bernton, E.W., J.E. Beach, J.W. Holaday, R.C. Smallridge, and H.G. Fein, Release of multiple hormones by a direct action of interleukin-1 on pituitary cells,Science238: 519–521, 1987.PubMedGoogle Scholar
  133. 133.
    Pardridge, W.M., Carrier-mediated transport of thyroid hormone through the rat blood-brain-barrier. Primary role of albumin-bound hormones,Endocrinology105: 605–612, 1979.PubMedGoogle Scholar
  134. 134.
    Pardridge, W.M., and L.J. Meitus, Transport of steroid hormone through the rat blood-brain-barrier: primary role of albumin-bound hormones, JClin Invest64: 145–154, 1979.PubMedGoogle Scholar
  135. 135.
    Kozlowski, G.P., Hormone pathways in cerebrospinal fluid, In E.A. Zimmerman and G. Abrams (eds)Neurologic Clinics: Neuroendocrinology and Brain Peptides, W.B. Saunders, Philadelphia, pp. 907–917, 1986.Google Scholar
  136. 136.
    Kozlowski, G.P., Ventricular route hypothesis and peptide-containing structures of the cerebroventricular system, In T.B. van Wimersma Greidanus (ed)Frontiers of Hormone Research, Volume9, S. Karger, Basel, pp. 105–118, 1982.Google Scholar
  137. 137.
    Hunter, W.M., and F.C. Greenwood, Preparation of 131 labelled human growth hormone of high specific activity,Nature194: 495–496, 1962.PubMedGoogle Scholar
  138. 138.
    Rettori, V., J. Jurčovčová, and S.M. McCann, Central action of interleukin-1 in altering the release of TSH, growth hormone, and prolactin in the male rat, JNeurosci Res18: 179–183, 1987.PubMedGoogle Scholar
  139. 139.
    Uehara, A., S. Gillis, and A. Arimura, Effects of interleukin-1 on hormone release from normal rat pituitary cells in primary culture,Neuroendocrinology45: 343–347, 1987.PubMedGoogle Scholar
  140. 140.
    Katsuura, G., and A. Arimura, Interleukin-lβ, Messenger of the immune signal to the neuroendocrine system, may act primarily on the hypothalamus: presence of its receptor in the hypothalamus, but not in the pituitary, of the rat,Enocrinology[Suppl] 122: 132, 1988.Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Gerald P. Kozlowski
    • 1
  • Gajanan Nilaver
    • 1
  • Berislav V. Zlokovič
    • 1
  1. 1.Department of PhysiologyUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations